Drugnews

What revenue guidance did Lilly give after Q3 2026?

On October 29, 2026, Eli Lilly raised its full-year 2026 revenue guidance from US$85–87 billion to US$91–92 billion, according to Drugnews’s November 2, 2026 analysis of the Mounjaro and Zepbound maker. This is company guidance for the full year, rather than completed annual sales.

Updated

Lilly full-year 2026 revenue guidance, US dollars
MeasureReported resultBasis
Previous rangeUS$85–87 billionBefore the quarterly update
Updated rangeUS$91–92 billionOctober 29, 2026 update

The original article also makes a prediction about the following year. That editorial prediction is separate from this company-issued guidance.

Sources

Read the full analysis

Lilly Cut Obesity Drug Prices 15% and Grew 39% — 2026-11-02